
CureVac Vaccine in EMA Rolling Review Process
German biotech CureVac has begun a rolling submission with the European Medicines Agency (EMA) for its mRNA-based Covid-19 vaccine candidate currently in Phase 2b/3 clinical trials with 35,000 people in Europe and Latin America.







































